CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
EUROPE
APAC
CANADA

About Us

Conference

Partner With Us

  • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Drug Discovery
    Antibodies
    BioTech
    Cell and Gene Therapy
    Clinical Trial
    Drug Discovery and Development
    Life Science AI
    Regenerative Medicine
    Therapeutics
  • Biomanufacturing
    Biomanufacturing
    Bioprocessing
    Blood Bank
    CDMO
    Clinical Laboratory
    CRO
    Life Science Testing
    Skin Care
    Supplements
  • Business Services
    Life Science Consulting
    Life Science Facility Service
    Life Science Financial Services
    Life Science Marketing
    Life Science Recruitment Firms
    Pharma Wholesale and Distribution
    Pharmacy Management
    Regulatory and Compliance
    Regulatory Services
  • Leadership Perspectives
  • Innovation Insights
  • Research
  • News
  • Magazines
  • CXO Awards
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

Accurate Clinical Research (ACR): Setting the Benchmark for Clinical Research Excellence

Accurate Clinical Research (ACR)

Setting the Benchmark for Clinical Research Excellence

When clinical trials are rooted in compliance and data quality, the payoff is clear; accelerated timelines, higher patient retention and on-time delivery of trial data that sponsors can act on without a second thought. Accurate Clinical Research (ACR) was built to deliver exactly that. It is one of the largest research site networks in the U.S. and has the most diverse patient population. Embedding quality and compliance into every layer of operations, ACR manages trials from Phase I through IV across numerous therapeutic areas, including rheumatology, cardiology, dermatology, gastroenterology, internal medicine, endocrinology, orthopedics, pediatrics, podiatry, urology and women’s health. From site management and regulatory guidance to patient recruitment and trial execution, ACR serves as a crucial link between sponsors, contract research organizations (CRO) and study participants to make breakthrough treatments possible. ACR sets itself apart by embracing a technology-first approach powered by a digital ecosystem. Its CRIO platform unifies CTMS, eSource and eReg in a single system to streamline clinical trial management. Large volumes of patient data are screened in record time by leveraging an AI-powered patient-matching platform. The process that once took months is now completed within 24 hours, accelerating study startup and improving site-sponsor collaboration. “We are solutions-driven and deeply operationally integrated, bringing experience and agility to clinical trial execution,” says Karen Obmaces, president and CEO. The trial data is time-stamped, transparent and remotely accessible to sponsors and monitors. They can log in to review data and documentation, reducing the need for frequent on-site visits and continuous oversight. Turning Operational Strength into Trial Success Agility is a core component of ACR’s operational model. Upon receiving the feasibility questionnaire and accompanying study synopsis, it inputs them into the AI platform. Protocol requirements are analyzed and matched with the most eligible candidates based on patient database compatibility and therapeutic alignment. The system then generates precise projections of potential patient availability for enrollment. These insights are submitted to the sponsor for informed site selection. The selected site undergoes a prestudy evaluation, where sponsors visit and assess ACR’s operational infrastructure and capabilities. Equipped with best-in-class technologies, fully calibrated systems and an experienced clinical team to efficiently initiate the trial, every ACR site gives sponsors the confidence to move forward with clarity.

Digital Magazine

Accurate Clinical Research (Acr): Setting The Benchmark For Clinical Research Excellence

Life Science Facility Service

Cleansol

Delivering Precision and Speed When It Matters Most

Eduardo Perez, President

Delays, cost overruns, failed inspections—these challenges don’t appear at the start of a project. They surface at the most critical moment: the end. That’s when every system must be commissioned, every surface must meet spec, and every failure can derail timelines by weeks or months. This is where Cleansol steps in. Specializing in technical cleaning and passivation for pharmaceutical and semiconductor projects across the U.S., Cleansol ensures that every surface is clean, compliant, and inspection-ready. But they don’t just show up with the right tools—they bring a plan, a team, and the speed to execute flawlessly. “Our job is to ensure everything is clean and compliant before turnover. But more than that, it’s to help our clients sleep at night,” says Eduardo Perez, Cleansol’s president. Solving Problems at Speed Speed isn’t just a perk for Cleansol—it’s their superpower. The company’s ability to mobilize trained teams quickly, scale operations to match project scope, and adapt to changing site conditions has made them a trusted partner when the pressure is highest. In one recent project, Cleansol started with a team of just four technicians working 10-hour shifts. As the client’s needs escalated, Cleansol scaled up to 30 personnel operating around the clock for nearly a year. This ability to scale without sacrificing quality or cohesion is rare. It’s not just about adding more people—it’s about deploying trained professionals who already know how to work together. “We’ll send a team of two for a small GMP suite or 30 for a mega fab. Either way, we treat it with urgency,” Perez explains. Cleansol’s speed also helps rescue projects already behind schedule. Clients often call them when everything is on the line—facing final inspections, turnover pressure, and performance qualifications that can’t be missed. Thanks to their investment in staff development, modular equipment and logistics, Cleansol can mobilize nationwide on short notice, with no red tape or drawn-out proposal processes—just a quick call, a fast quote, and a crew on-site..

Life Science Marketing

Return on Focus

The Strategic Work That Defines Pharma Success

Dan Reinhardt, President and Abby Manning, Managing Partner

In the world of pharma and biotech, getting the commercial foundation right is just as critical as advancing the science. At the center of effective marketing lies a focused narrative. It must be uncovered early and maintained consistently throughout development, launch, and beyond. This is where many teams struggle. Without a strong narrative, even the most promising therapies can be misunderstood, failing to reach their full potential. Brands must cut through the noise, align internally, and speak clearly to every stakeholder, from investors to physicians. That’s where the right partner becomes mission-critical to shaping those conversations. This is where Return on Focus (ROF) concentrates. ROF is a strategic marketing organization that helps pharmaceutical and biotech brands unlock their market value. Through evidence-based positioning and messaging, ROF guides teams in crafting compelling brand stories that drive behavior change and ensure the right medicines reach the right patients. “What sets ROF apart is their unique approach. While frameworks may guide their work, each engagement is a data-driven investigation that yields bespoke solutions. It’s also impressive that after all these years, the owners still roll up their sleeves and do the work. Their recommendations benefit from their combined decades of experience and wisdom,” says Deborah Glasser, Head of Sanofi Specialty Care, North America and U.S. Country Lead. Finding clarity across every stage of growth While its clients range in size, many operate in complex, high-impact categories such as oncology, immunology, and rare disease. ROF typically engages across three stages of a brand’s lifecycle. In early development, it helps lay the foundation for how a product will be positioned as proof of concept data emerges. By Phase 3, the focus shifts to launch preparation, message alignment, and stakeholder readiness. Even after approval, ROF remains a critical partner as the market changes and new indications arise. Post-launch, it supports brands facing competitive or data shifts, helping teams evolve strategy and communications. Its approach ensures strategic evolution keeps pace with science so brands stay consistent and focused in an evolving space. “ROF are true strategic specialists and they offer a systematic process that incorporates customer insights to deliver clear and decisive roadmaps to launch success,” says William Jenkinson, Executive Director of Marketing, Merus..

Supplements

The Significant Increase in Demand for Clinical Research Associates (CRAs)

Helen Yeardley, Executive Vice President, ICON [NASDAQ: ICLR]

Therapeutics

Modular approach for Large Scale Cell Culture CDMO facilities

Jacob Gronnegaard, Director Automation, FUJIFILM Diosynth Biotechnologies

CRO

Navigating the Evolution and Future of Charge Variant Analysis in Biopharmaceutical Development

Roxana McCloskey, Senior Global Marketing Manager BioPharma, and Zoe Zhang, Senior Manager, Biopharma Applications, SCIEX

Clinical Trial

Flexibility to Change is the Key to Successful Pharma Projects

Carrie Lewis, Executive Director, Clinical Program Optimization, Endo International

CDMO

Agility as the Superpower for Clinical Operations

John Benedetto, VP and Global Head of Clinical Development Operations, BioNTech SE

IN MY OPINION

Regulatory Services

Accelerating Early-Stage Drug Development

Safwan Kezbor, M.D., Global Medical Lead (Senior Medical Director), Clinical Development, Shionogi Inc

LAST WORD

Drug Discovery and Development

A Vision for the Future of Clinical Research

Marti Gardner, System Director, Clinical Research Operations, Norton Healthcare

IN FOCUS

Reengineering Clinical Trials: The New Architecture of Adaptive, Decentralized, Data-Driven Research

Service providers are transforming clinical trials by adopting adaptive models, decentralizing participation, and integrating real-world data, making research more efficient and patient-focused.

Learn more

Passivation Reimagined: Outsourcing Integrity in the Age of Complex Formulations

Pharmaceutical manufacturing increasingly relies on "Passivation as a Service," outsourcing specialized passivation processes to enhance equipment safety, efficiency, and compliance across multiple sites.

Learn more

EDITORIAL

Forging the Future of Biopharma Innovation

The pharmaceutical sector is undergoing rapid evolution, with shifting regulations and the rising impact of technologies reshaping the journey from research to commercialization. For companies to stay competitive and meet complex market and regulatory requirements, embracing these innovations has become essential.

AI-driven analytics and predictive modeling are transforming pharma consulting by enabling precise market forecasting and optimized product launches. Automated monitoring systems and real-time environmental sensors are enhancing pharmaceutical passivation services, helping maintain sterile and compliant conditions. Digital platforms, AI-assisted patient matching and eSource systems are accelerating clinical research studies by streamlining the trial process and improving data integrity. Together, these technologies are bridging the gap between laboratory research and market-ready therapies with unprecedented speed and accuracy.

This edition of Life Sciences Review explores how the biopharmaceutical industry leverages cutting-edge technology and operational strategies to bring medicines to market more efficiently and improve patient outcomes.

Featured thought leaders include Roxana McCloskey, senior global marketing manager, biopharma, and Zoe Zhang, senior manager, biopharma applications at SCIEX. They explain how integrated technologies like the Intabio ZT system streamline charge variant analysis to accelerate drug development while improving product safety and quality.

Jacob Gronnegaard, Director Automation at FUJIFILM Diosynth Biotechnologies, emphasizes how the biopharmaceutical industry is increasingly adopting modular and standardized manufacturing to respond swiftly to changing demands and technological advancements.

This edition also features Accurate Clinical Research (ACR), a leading U.S.-based clinical research organization that accelerates clinical trials by combining operational excellence with patient-centered care and advanced technology.

We hope this edition inspires you with insights into the transformative approaches shaping modern pharmaceutical research and production.

Life Sciences Review
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review. All rights reserved. Headquartered in Fort Lauderdale, FL, USA.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/edition/october-15-2025-56.html